Magnetar Financial LLC Buys Shares of 15,500 SI-BONE, Inc. (NASDAQ:SIBN)

Magnetar Financial LLC purchased a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 15,500 shares of the company’s stock, valued at approximately $217,000.

A number of other hedge funds have also made changes to their positions in the stock. FMR LLC lifted its holdings in SI-BONE by 103.6% in the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after purchasing an additional 1,198 shares during the last quarter. Mainstream Capital Management LLC bought a new position in shares of SI-BONE in the fourth quarter valued at approximately $53,000. R Squared Ltd acquired a new stake in shares of SI-BONE in the fourth quarter worth $73,000. Walleye Capital LLC bought a new stake in shares of SI-BONE during the 3rd quarter worth $144,000. Finally, Proficio Capital Partners LLC acquired a new position in SI-BONE in the 4th quarter valued at $155,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Activity at SI-BONE

In other news, CFO Anshul Maheshwari sold 5,304 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the transaction, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now owns 222,814 shares in the company, valued at $3,097,114.60. This represents a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,311 shares of company stock worth $130,356. 3.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Needham & Company LLC upped their price target on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $22.00 price target (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, SI-BONE currently has a consensus rating of “Buy” and a consensus target price of $24.50.

SI-BONE Stock Down 2.0 %

Shares of NASDAQ:SIBN opened at $14.66 on Monday. The company has a 50 day moving average of $16.62 and a 200-day moving average of $14.80. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $19.16. The stock has a market cap of $622.36 million, a price-to-earnings ratio of -15.93 and a beta of 1.17. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $49.00 million during the quarter, compared to analysts’ expectations of $48.87 million. On average, sell-side analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.